Objectives: To describe the clinicopathologic findings of seven patients with CD5-positive nodal marginal zone lymphoma (NMZL).
Methods: We searched cases of NMZL over a 10-year interval and identified seven cases of CD5-positive NMZL. The clinical, histologic, and immunophenotypic findings of this group were reviewed, and the frequency of dissemination in this group was compared with that of 66 patients with CD5-negative NMZL.
Results: Other than CD5 expression, the histologic and immunophenotypic findings were typical of NMZL. Six (86%) of seven patients had lymphadenopathy above and below the diaphragm, and all six patients assessed had bone marrow involvement. In the CD5-negative group, 28 (42%) patients had lymphadenopathy above and below the diaphragm, and 36 (55%) had bone marrow involvement (P = .045 and P = .037, respectively). Six of seven patients were alive at last follow-up, with a median follow-up of 32 months (3-154 months).
Conclusions: CD5 expression in NMZL correlates with a higher frequency of dissemination, but patients have an indolent clinical course and excellent overall survival.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1309/AJCPEMVXES72DUIF | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study.
Cancer Med
October 2022
Service d'hématologie clinique, Centre Hospitalier Universitaire Nantes, Nantes, France (at the time of work), Service d'hématologie - Centre Hospitalier Bretagne Atlantique, Vannes, France (now).
Background: Intravascular large B-cell lymphoma (lVLBCL) is a very rare type of large B-cell lymphoma.
Methods: We conducted a retrospective study on IVLBCL patients treated from 2000 to 2016 in LYSA cooperative group centers.
Results: Sixty-five patients were identified in 23 centers.
Immunohistochemistry for LEF1 and SOX11 adds diagnostic specificity in small B-cell lymphomas.
Hum Pathol
March 2022
Division of Hematopathology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905 United States.
Lymphocyte enhancer-binding factor 1 (LEF1) and SRY-Box 11 (SOX11) are highly sensitive and specific for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) including the cyclin D1-negative subtype, respectively. We assessed the utility of these markers in a large cohort of small B-cell lymphomas (SBCLs) on varied sample types. Immunohistochemistry (IHC) was performed for LEF1 and SOX11 on 354 SBCLs (129 CLL/SLLs, 33 MCLs, 142 marginal zone lymphomas [MZLs]-nodal MZL [NMZL]: 40, extranodal MZL [ENMZL]: 28, splenic MZL [SMZL]: 74 cases-and 50 lymphoplasmacytic lymphomas [LPLs]/Waldenstrom macroglobulinemias [WMs]).
View Article and Find Full Text PDFHow to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.
Curr Oncol
November 2021
Department of Hematology, Portuguese Institute of Oncology Lisbon, 1099-023 Lisboa, Portugal.
Patients with CD5-expressing lymphomas presenting with splenomegaly are frequently diagnosed with chronic lymphocytic leukemia. The most important differential diagnosis is mantle cell lymphoma, both in its classical and leukemic, non-nodal forms, given its prognostic and therapeutic implications. Other small B-cell neoplasms that frequently involve the spleen and occasionally express CD5 include the splenic marginal zone lymphoma, hairy cell leukemia and, rarely, lymphoplasmacytic lymphoma.
View Article and Find Full Text PDFAdult Nodal Burkitt Lymphoma Forming Nodular Architectures.
Cureus
October 2021
Department of Diagnostic Pathology, Shimada City General Medical Center, Shimada, JPN.
In this report, we discuss a case of nodal Burkitt lymphoma seen in a 60-year-old Japanese male patient. Microscopic features of the biopsied 30 mm-sized cervical lymph node revealed nodular architectures with starry sky appearance surrounded by small mantle zone B-lymphocytes. Immunohistochemical and molecular studies demonstrated typical features of sporadic Burkitt lymphoma: the atypical cells were positive for CD20, CD79a, CD10, CD23, HLA-DR, bcl-6, PAX5, c-myc, and cytoplasmic IgM, but negative for CD3, CD5, CD15, CD30, CD34, TdT, bcl-2, and MUM1.
View Article and Find Full Text PDFCD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage.
Leuk Lymphoma
April 2022
Section of Hematology and Medical Oncology, Department of Medicine, Tulane University, New Orleans, LA.
Conventionally, mantle cell lymphoma (MCL) is an aggressive CD5-positive B-cell malignancy with poor prognosis and limited survival. However, a small subset of patients presents with indolent disease and can be managed on a 'watch and wait' approach. CD5-negative MCL has recently been recognized as a more favorable variant of MCL, but its clinical and biological implications remain ill-defined.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!